Hematuria differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
!
! colspan="3" rowspan="5" |'''Gold standard'''
!
!
!
!
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
|-
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examina
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examina
!tion
!
!
!
!
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosi
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosi
! colspan="0" rowspan="3" |CT scans method
! colspan="0" rowspan="3" |CT scan
!
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
Line 47: Line 32:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pitting edema
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pitting edema
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
|-
|-
Line 53: Line 37:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|-
|-
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glomerular disease|Glomerular diseases]]
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glomerular disease|Glomerular diseases]]
Line 69: Line 51:
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | '''Biopsy:'''  
| style="background: #F5F5F5; padding: 5px;" | '''Biopsy:'''  
IgA deposited in a diffuse granular patte
IgA deposited in a diffuse granular patte-rn in the mesangium
| style="background: #F5F5F5; padding: 5px;" | -rn in the mesangium
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |
*  
*  
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
Line 99: Line 75:
| style="background: #F5F5F5; padding: 5px;" |'''Biopsy:'''
| style="background: #F5F5F5; padding: 5px;" |'''Biopsy:'''
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of typ-e IV collagen
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of typ-e IV collagen
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Genetic analysis
* High-frequency sensorineural hearing loss
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of type IV collagen
| style="background: #F5F5F5; padding: 5px;" |
* Genetic Analysis
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
Line 131: Line 101:
* Immunoglobulin G and C3 in a diffuse granular pattern  
* Immunoglobulin G and C3 in a diffuse granular pattern  
* Starr-y sky pattern
* Starr-y sky pattern
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
Line 162: Line 127:
* Segmental solidification in the perihilar region and  peripheral areas, specially the tubular pole
* Segmental solidification in the perihilar region and  peripheral areas, specially the tubular pole
* Coarsely granular deposits -of IgM and C3
* Coarsely granular deposits -of IgM and C3
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
Line 195: Line 154:
| style="background: #F5F5F5; padding: 5px;" | Biopsy:
| style="background: #F5F5F5; padding: 5px;" | Biopsy:
* Diffuse, proliferative, necrotizing glomerulonephritis with cresc-ent formation
* Diffuse, proliferative, necrotizing glomerulonephritis with cresc-ent formation
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | 80% of patients have ANCA-positive microscopic polyangiitis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Biospy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 222: Line 177:
| style="background: #F5F5F5; padding: 5px;" | Biopsy,  
| style="background: #F5F5F5; padding: 5px;" | Biopsy,  
* Different pathologies, [[Lupus nephritis|CLICK HERE]] for more- information.
* Different pathologies, [[Lupus nephritis|CLICK HERE]] for more- information.
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
Line 243: Line 194:
* Proteinuria
* Proteinuria
| style="background: #F5F5F5; padding: 5px;" | Biopsy
| style="background: #F5F5F5; padding: 5px;" | Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
| colspan="2" style="background: #F5F5F5; padding: 5px;" | Biopsy
| style="background: #F5F5F5; padding: 5px;" |Non-specific+/- nephrotic picture
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
Line 262: Line 209:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
Line 285: Line 229:
* [[Edema]] and infiltration by mononuclear cells, (principally lymphocytes)
* [[Edema]] and infiltration by mononuclear cells, (principally lymphocytes)
* [[Eosinophils]] are present, often in large numbers.  
* [[Eosinophils]] are present, often in large numbers.  
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 312: Line 252:
* Hydronephrosis +/- in sonography
* Hydronephrosis +/- in sonography
* Abdominal CT scan without contrast
* Abdominal CT scan without contrast
| style="background: #F5F5F5; padding: 5px;" |Abdominal Ct scan without contrast
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |Abdominal Ct scan without contrast
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
|-
|-
Line 341: Line 278:


* Biopsy: Kidney scar
* Biopsy: Kidney scar
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 366: Line 300:
* Both [[CT]] and [[MRI]] may be used to detect [[neoplastic]] masses that may define renal cell carcinoma or metastasis of the primary cancer. [[CT]] scan and use of intravenous (IV) contrast is generally used for work-up and follow-up of patients with [[Renal cell carcinoma|renal cell carcinom]]<nowiki/>a.
* Both [[CT]] and [[MRI]] may be used to detect [[neoplastic]] masses that may define renal cell carcinoma or metastasis of the primary cancer. [[CT]] scan and use of intravenous (IV) contrast is generally used for work-up and follow-up of patients with [[Renal cell carcinoma|renal cell carcinom]]<nowiki/>a.
* The histological pattern of renal cell [[carcinoma]] depends whether it is [[Papillary|papillary,]] [[chromophobe]] or [[collecting duct]] renal cell carcinoma.
* The histological pattern of renal cell [[carcinoma]] depends whether it is [[Papillary|papillary,]] [[chromophobe]] or [[collecting duct]] renal cell carcinoma.
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 400: Line 331:
**[[Adipose tissue|Fat tissue]]
**[[Adipose tissue|Fat tissue]]
**[[Fibrous connective tissue|Fibrous tissue.]]
**[[Fibrous connective tissue|Fibrous tissue.]]
| style="background: #F5F5F5; padding: 5px;" |
*Wilms tumor has a triphasic appearance.
*It is comprised of 3 types of cells:
**[[Stromal]]
**[[Epithelium|Epithelial]]
**[[Blastema|Blastemal]]
*All the 3 types are not required for the diagnosis of Wilms tumor.
*
*Beckwith and Palmer reported in NWTS the different histopathologic types of Wilms tumor to categorize them based on prognosis.<ref name="pmid1978">{{cite journal |vauthors=Jolly RD, Stellwagen E, Babul J, Vodkaĭlo LV, Titov VL, Moldomusaev DM, Maianskiĭ AN |title=Mannosidosis of Angus Cattle: a prototype control program for some genetic diseases |journal=Adv Vet Sci Comp Med |volume=19 |issue=23 |pages=1–21 |date=November 1975 |pmid=1978 |doi= |url=}}</ref>
**
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 430: Line 348:
* [[Hematuria]]
* [[Hematuria]]
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 450: Line 365:
* [[Hematuria]]
* [[Hematuria]]
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 469: Line 381:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
Line 512: Line 421:
* Thickening and lamellation of tubular basement membranes
* Thickening and lamellation of tubular basement membranes
* Microcysts
* Microcysts
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Ultrasound
| style="background: #F5F5F5; padding: 5px;" |Ultrasound
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 541: Line 446:
* Ultrasound,
* Ultrasound,
* Venography
* Venography
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |'''Renal venography:''' Gold standard
| style="background: #F5F5F5; padding: 5px;" |'''Renal venography:''' Gold standard
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 574: Line 476:
* Microthrombosis, and
* Microthrombosis, and
* [[Degranulation]] of [[neutrophils]].
* [[Degranulation]] of [[neutrophils]].
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
* Subendothelial [[edema]]
* Microthrombosis, and
* [[Degranulation]] of [[neutrophils]].
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 604: Line 499:


IgA deposited in a diffuse granular pattern in the mesangium
IgA deposited in a diffuse granular pattern in the mesangium
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy, and clinical syndrome
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy, and clinical syndrome
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 623: Line 515:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
Line 655: Line 544:
* Urine cytology to screen for bladder cancer
* Urine cytology to screen for bladder cancer
* Biopsy to rule out cancer
* Biopsy to rule out cancer
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 667: Line 552:
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 681: Line 563:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Interstitial cystitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Interstitial cystitis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 699: Line 578:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Radiogenic|Radiogenic cystitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Radiogenic|Radiogenic cystitis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 718: Line 594:
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Systemic diseases]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Systemic diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemophilia|Coagulopathy (hemophilia)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemophilia|Coagulopathy (hemophilia)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 736: Line 609:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sickle cell anemia]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sickle cell anemia]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 754: Line 624:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Abdominal aortic aneurysm]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Abdominal aortic aneurysm]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 772: Line 639:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphomas]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphomas]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 790: Line 654:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Multiple myeloma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Multiple myeloma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 820: Line 681:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
Line 847: Line 705:
* Hypodense appearance
* Hypodense appearance
* [[Abscess|Abscesses]] may not be present
* [[Abscess|Abscesses]] may not be present
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 874: Line 729:


* Also help to detect the presence of a [[tumor]] or a [[Stone massage|stone]].
* Also help to detect the presence of a [[tumor]] or a [[Stone massage|stone]].
| style="background: #F5F5F5; padding: 5px;" |
*
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Urine culture
| style="background: #F5F5F5; padding: 5px;" |Urine culture
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 901: Line 752:
CT scan:  
CT scan:  
* Edema of the [[prostate gland]] with diffuse enlargement,.
* Edema of the [[prostate gland]] with diffuse enlargement,.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 926: Line 774:
* Diffuse, circumferential urothelial wall thickening and contrast-enhancement
* Diffuse, circumferential urothelial wall thickening and contrast-enhancement
* Periureteric or perinephric fat stranding.
* Periureteric or perinephric fat stranding.
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 941: Line 786:
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 952: Line 794:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 16:57, 1 February 2019

Hematuria Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hematuria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hematuria differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hematuria differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hematuria differential diagnosis

CDC on Hematuria differential diagnosis

Hematuria differential diagnosis in the news

Blogs on Hematuria differential diagnosis

Directions to Hospitals Treating Hematuria

Risk calculators and risk factors for Hematuria differential diagnosis

Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Omer Kamal, M.D.[1], Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [2]

Overview

Gross hematuria(GH) must be distinguished from pigmenturia, which may be due to endogenous sources (e.g., bilirubin, myoglobin,and porphyrins), foods ingested (e.g., beets and rhubarb), drugs (e.g., phenazopyridine), and simple dehydration. This distinction can be made easily by urinalysis with microscopy. Notably, myoglobinuria and other factors can cause false-positive chemical tests for hemoglobin, so urine microscopy is required to confirm the diagnosis of hematuria. GH also must be distinguished from vaginal bleeding in women, which usually can be achieved by obtaining a careful menstrual history, collecting the specimen when the patient is not having menstrual or gynecologic bleeding, or, if necessary, obtaining a catheterized specimen. GH may also be detected by the presence of blood spotting on the undergarments of incontinent patients. After ruling out vaginal bleeding and mimics of hematuria, a urologic source must be suspected.

Differential Diagnosis

Hematuria should be differentiated from other disease which mimic hematuria especially hemoglobinuria and myoglobinuria which are dipstick positive but negative for microscopy.

Hematuria differential diagnosis

Differentiating the diseases that can cause hematuria:

Diseases Clinical manifestations Para-clinical findings Gold standard
Symptoms Physical examina
Lab Findings Diagnosi
Low back pain Fever Nausea/

Vomiting

Urinary symptoms Hypertension Pitting edema Other
Dysuria Frequency Oliguria
Glomerular diseases IgA nephropathy (Berger nephropathy) + - - - + + + - - Biopsy:

IgA deposited in a diffuse granular patte-rn in the mesangium

Biopsy
-
Hereditary nephritis (Alport syndrome) - - - - - - + -
  • Cataract
  • Hearing loss
Biopsy:
  • Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of typ-e IV collagen
  • Genetic analysis
-
Poststreptococcal glomerulonephritis +/- + - - + + + +
  • Edema
  • Anemia
  • Increased Blood Pressure
  • Urine samples for protein and blood

Biopsy

  • Irregularly thin and attenuated GBM
  • Splitting of GBM
  • Scarring
  • Immunoglobulin G and C3 in a diffuse granular pattern
  • Starr-y sky pattern
Biopsy -
Focal segmental glomerular sclerosis - - - - - - + +
  • Nephrotic syndrome
  • ESRD
  • Pleural effusion
  • Ascites
  • Abdominal pain
  • Urinalysis reveals large amounts of protein, along with hyaline and broad waxy casts
  • Hepatitis B or C infection
  • Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis
Biopsy
  • Segmental solidification in the perihilar region and peripheral areas, specially the tubular pole
  • Coarsely granular deposits -of IgM and C3
Biopsy -
Rapidly progressive glomerulonephritis + + + - - - + -
  • Abdominal pain
  • Painful cutaneous nodules
  • Migratory polyarthropathy
  • Sinusitis
  • Cough
  • Hemoptysis.
  • Low iron
  • Eosinophilia
  • Increased serum creatinine level
  • Eleated LDH and CPK
  • Proteinuria
Biopsy:
  • Diffuse, proliferative, necrotizing glomerulonephritis with cresc-ent formation
Biopsy
Lupus nephritis - + - - - - + +
  • Foamy dark urine
  • Weight gain
Biopsy,
  • Different pathologies, CLICK HERE for more- information.
Biopsy -
Fabry disease - - - - - - + + -
  • Hematuria
  • Proteinuria
Biopsy Biopsy
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard Additional findings
Tubulointerstitial diseases + + + Rash Biopsy:
  • Edema and infiltration by mononuclear cells, (principally lymphocytes)
  • Eosinophils are present, often in large numbers.
Renal biopsy
Nephrolithiasis + ± + ± ± ±
  • Radiating pain to groin
  • Hydronephrosis +/- in sonography
  • Abdominal CT scan without contrast
Abdominal Ct scan without contrast
Reflux nephropathy (hydronephrosis) + + - - - - - +
  • Elevated WBC count
  • Elevated BUN
  • Hyperkalemia
  • Ultrasound: Hydronephrosis +/-
  • Biopsy: Kidney scar
Malignancy Renal cell carcinoma (RCC) - - - - - - ± ±
  • Flank mass
  • Anemia
  • Hematuria
Nephroblastoma (Wilms tumor) - - - - - - - -
  • Abdominal pain

Biopsy:

Biopsy
Bladder cancer - - - - ± ± - - Suprapubic pain Ultrasound, CT scan, Biopsy Biopsy
Prostate cancer ± - - - ± ± - - - Ultrasound, CT scan, Biopsy Biopsy
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard Additional findings
Familial diseases Polycystic kidney disease + - - - - - + + Ultrasound:
  • Unilateral or bilateral cysts

CT:

  • Hyperdense appearance,
  • Septations
  • Calcifications

Genetic testing demonstrates:

  • Frame insertions/deletions
  • Non-canonical splice site alterations
  • Combined missense changes

Biopsy:

  • Interstitial fibrosis
  • Tubular atrophy
  • Thickening and lamellation of tubular basement membranes
  • Microcysts
Ultrasound
Vascular diseases Renal vein thrombosis + + + - - - - -
  • Asymptomatic
  • Abdominal pain
  • Acute in onset
  • Elevation in serum lactate dehydrogenase
  • Cholesterol levels for hypercholesterolemia
  • Albumin levels for hypoalbuminemia
  • Serum complement levels
  • Ultrasound,
  • Venography
Renal venography: Gold standard
Wegner's granulomatosis polyangiitis - - - - - +/- + +
  • URTI
  • CNS involvement
  • Ophthalmic involvement
  • Proteniuria
  • Microscopic hematuria
  • RBC casts
CT chest:

Biopsy:

Biopsy
Henoch-Schönlein purpura - - - - - +/- +/- +
  • Abdominal pain
  • Rash
  • Hematuria
  • Proteniuria
  • Microscopic hematuria
  • RBC casts
Biopsy:

IgA deposited in a diffuse granular pattern in the mesangium

Renal biopsy, and clinical syndrome
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard Additional findings
Lower urinary tract diseases Benign prostatic hyperplasia +/- - - + + - - -
  • Nocturia
  • Other voiding symptoms
    • Slow urinary stream
    • Splitting or spraying of the urinary stream
    • Intermittent urinary stream
    • Hesitancy
    • Straining to void
    • Terminal dribbling
  • Urinalysis to rule out UTI
  • Elevated BUN/Cr
  • High PSA values
  • Urine cytology to screen for bladder cancer
  • Biopsy to rule out cancer
Biopsy
Urolithiasis + +/- + +
Interstitial cystitis
Radiogenic cystitis
Systemic diseases Coagulopathy (hemophilia)
Sickle cell anemia
Abdominal aortic aneurysm
Lymphomas
Multiple myeloma
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard Additional findings
Infectious diseases Pyelonephritis + + + + + + - - CT and ultrasound:
  • Enlarged kidneys
  • Round swollen kidneys
  • Hypodense appearance
  • Abscesses may not be present
-
Cystitis - - - + + + - -
  • Ultrasound:
  • Presence of a gas in the bladder wall.
  • Also help to detect the presence of a tumor or a stone.
Urine culture
Prostatitis - + - + + + - -
  • Body aches
Ultrasound:
  • Focal hypoechoic region located in the peripheral part of the prostate

CT scan:

-
Urethritis -/- + - + + + - -
  • Urethral discharge

CT scan:

  • Diffuse, circumferential urothelial wall thickening and contrast-enhancement
  • Periureteric or perinephric fat stranding.
Epididymitis -/+ + + - - - - -
Urogenital trauma Inserted bladder or ureteral catheters

References

  1. Hartman DS, Sanders RC (April 1982). "Wilms' tumor versus neuroblastoma: usefulness of ultrasound in differentiation". J Ultrasound Med. 1 (3): 117–22. PMID 6152936.
  2. De Campo JF (1986). "Ultrasound of Wilms' tumor". Pediatr Radiol. 16 (1): 21–4. PMID 3003660.
  3. Cahan LD (1985). "Failure of encephalo-duro-arterio-synangiosis procedure in moyamoya disease". Pediatr Neurosci. 12 (1): 58–62. PMID 4080660.

Template:WH Template:WS